Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
KEGG DRUG: Neratinib maleate
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting | Business Wire
Nerlynx: Package Insert / Prescribing Information - Drugs.com
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Puma Biotechnology
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
PUMA BIOTECHNOLOGY: Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
Neratinib Nerlynx Tablet, Puma Biotechnology, Bottle at Rs 5000/bottle in Nagpur
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Nerlynx (neratinib) Cancer Medication - Cancer Health
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma